ORLANDO, FL / ACCESSWIRE / January 5, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of transdermal...
Fiscal Year 2024 Second Quarter Highlights Net sales of $79.1 million increased 2.7% on a pro-forma basis compared to the...
Rohit Gupta, a Nationally Recognized Scientist, Biobank and Data Expert, is Named as Metrodora Institute's New Chief Scientific Officer and...
NEW YORK, NY / ACCESSWIRE / January 5, 2024 / Zen Dog Veterinary Care, New York City's premier in-home pet...
Head-to-head comparison with licensed bivalent mRNA-based comparator vaccine confirms competitive immune responses at lower doses and favorable tolerability profileMonovalent mRNA...
Establishes Leading Platform of Complementary Multi-omic Technologies with Enhanced Scale and Commercial Reach; Strengthened Balance Sheet to Self-Fund Future Growth...
- EU Clinical Trials authorized for Phase 1b/2a SPOTLIGHT and BEACON studies of briquilimab in CIndU and CSU, respectively -...
JERSEY CITY, N.J., Jan. 05, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to...
If approved, DFD-29 has potential to be best-in-class and the only oral medication to address both inflammatory lesions and erythema...
TORONTO and HAIFA, Israel , Jan. 05, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the...
PLEASANTON, Calif., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Healthcare Triangle, Inc. (Nasdaq: HCTI) (“Healthcare Triangle,” “HCTI” or the “Company”), a leader...
WOBURN, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Axial Therapeutics, a clinical-stage biotechnology company dedicated to the development of gut-targeted,...
In 2H 2024, expect to provide Phase 2a topline proof-of-concept data from our wholly-owned lead program SPR720 in NTM-PD patients...
CORAL GABLES, Fla., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or the “Company”) (Nasdaq: CPRX) announced today...
Enrollment in dose escalation and backfill cohorts continuing in Phase 1 clinical trial of XMT-1660, Dolasynthen B7-H4 ADC; expect to...
Lykos Therapeutics, formerly known as MAPS PBC, announced the close of Series A financing to support regulatory and pre-launch activities...
CAMBRIDGE, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a...
Acquisition Expected to Contribute More than $8 Million of Annualized Revenue and Positive Net IncomeMIAMI, Jan. 05, 2024 (GLOBE NEWSWIRE)...
Portage, Michigan, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that it will report financial results for fourth quarter...
ReWalk Personal Exoskeleton covered as a medically necessary device for an eligible Medicare beneficiary with spinal cord injuryMARLBOROUGH, Mass. and...